Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 21Leukemia 6Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 37fludarabine phosphate 27Whole-Body Irradiation 26Cytarabine 26Mycophenolic Acid 22Methotrexate 20Filgrastim 19Peripheral Blood Stem Cell Transplantation 18Cyclosporine 18fludarabine 17venetoclax 15Busulfan 13Tacrolimus 12Granulocyte Colony-Stimulating Factor 12Cord Blood Stem Cell Transplantation 12Thiotepa 11Antilymphocyte Serum 11Melphalan 10Azacitidine 10Dexamethasone 9Cladribine 9Vincristine 8Specimen Handling 8Radiotherapy 8Mitoxantrone 8Methylprednisolone 8Idarubicin 7Cyclosporins 7Clofarabine 7Hydrocortisone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Biphenotypic, Acute × Homoharringtonine × Clear all
NCT04874194 2025-11-03

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

M.D. Anderson Cancer Center

Phase 1/2 Terminated
24 enrolled 15 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡